- Home
- SYRE vs UCTT Comparison
SYRE vs UCTT Comparison
Compare SYRE & UCTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- UCTT
- Stock Information
- Founded
- SYRE 2013
- UCTT 1991
- Country
- SYRE United States
- UCTT United States
- Employees
- SYRE N/A
- UCTT N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- UCTT Semiconductors
- Sector
- SYRE Health Care
- UCTT Technology
- Exchange
- SYRE Nasdaq
- UCTT Nasdaq
- Market Cap
- SYRE 841.4M
- UCTT 910.7M
- IPO Year
- SYRE 2016
- UCTT 2004
- Fundamental
- Price
- SYRE $15.30
- UCTT $19.37
- Analyst Decision
- SYRE Buy
- UCTT Strong Buy
- Analyst Count
- SYRE 6
- UCTT 4
- Target Price
- SYRE $55.00
- UCTT $43.25
- AVG Volume (30 Days)
- SYRE 490.0K
- UCTT 499.2K
- Earning Date
- SYRE 05-08-2025
- UCTT 07-24-2025
- Dividend Yield
- SYRE N/A
- UCTT N/A
- EPS Growth
- SYRE N/A
- UCTT N/A
- EPS
- SYRE N/A
- UCTT 0.62
- Revenue
- SYRE N/A
- UCTT $2,138,500,000.00
- Revenue This Year
- SYRE N/A
- UCTT N/A
- Revenue Next Year
- SYRE N/A
- UCTT $1.85
- P/E Ratio
- SYRE N/A
- UCTT $31.47
- Revenue Growth
- SYRE N/A
- UCTT 20.21
- 52 Week Low
- SYRE $10.91
- UCTT $16.66
- 52 Week High
- SYRE $40.26
- UCTT $56.47
- Technical
- Relative Strength Index (RSI)
- SYRE 51.16
- UCTT 41.08
- Support Level
- SYRE $14.87
- UCTT $19.34
- Resistance Level
- SYRE $15.71
- UCTT $20.98
- Average True Range (ATR)
- SYRE 0.72
- UCTT 0.79
- MACD
- SYRE 0.10
- UCTT -0.12
- Stochastic Oscillator
- SYRE 51.57
- UCTT 10.26
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About UCTT Ultra Clean Holdings Inc.
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.